Hepatic tolerance of atypical antipsychotic drugs;Tolérance hépatique des antipsychotiques atypiques

Encephale

Volumn 28, Issue 6 I, 2002, Pages 542-551

  Dumortier, G ^a   Cabaret, W ^a   Stamatiadis, L ^a   Saba, G ^a   Benadhira, R ^a   Rocamora, J F ^a   Aubriot delmas, B ^a   Glikman, J ^a   Januel, D ^a  

^a NONE

Author keywords

Antipsychotic drug; Hepatic tolerance; Side effects

Indexed keywords

'ATRIUM'; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPIDEM; AMISULPRIDE; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; CLOZAPINE; GAMMA GLUTAMYLTRANSFERASE; HALOPERIDOL; LIVER ENZYME; MEDIFOXAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; RISPERIDONE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHCET DISEASE; CHOLESTATIC HEPATITIS; COCAINE DEPENDENCE; CONVULSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ECHOGRAPHY; EOSINOPHILIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS; HUMAN; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER INJURY; LIVER TOXICITY; NEGATIVE SYNDROME; PATIENT COMPLIANCE; PNEUMONIA; RISK FACTOR; SUICIDE ATTEMPT; TOXIC HEPATITIS; TREMOR;

EID: 17944390285     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. COLLABORATIVE WORKING GROUP ON CLINICAL EVALUATIONS. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 59 (Suppl 12): 17-22.
2. BARNES TR, McPHILLIPS MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 1999; 174 (Suppl 38): 34-43.
3. BAUER M. Concurrent agranulocytosis and acute hepatitis resulting from combination of classic neuroleptics and subsequent clozapine treatment. Pharmacopsychiatry 1995; 28: 29-31.
4. BÉGAUD B, EVREUX JC, JOUGLARD J et al. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode en France. Thérapie 1985; 40: 111-8.
5. BENAZZI F. Risperidone-induced hepatotoxicity. Pharmacopsychiatry 1998; 31 (6): 241.
6. e éd. Pradel, 1996.
7. e mise à jour du ficher bíblíographíque des atteintes hépatiques et des médicaments responsables. Gastroenterol Clin Biol 2000; 24: 1052-91.
8. BOELSTERLI UA, BOUIS P, DONATSCH P. Relative cytotoxicity of psychotropic drugs in cultured rat hepatocytes. Cell BiolToxicol 1987; 3 (3): 231-50.
9. BRODOWSKI L, MATUSEWICZ W, URBANSKA-RYS H et al. Acute bone marrow and liver damage during treatment with clozapine. Pol Tyg Lek May 1984; 39 (21): 721-2.
10. BROWN CS, MARKOWITZ JS, MOORE TR et al. Atypical antipsychotics: Part II. Adverse effects, drug interactions and costs. Ann Pharmacother 1999; 33: 210-7.
11. CADARIO B. Olanzapine (Zyprexa*): suspected serious reactions. CMAJ 2000; 163 (1): 85-6.
12. CONLEY RR, MELTZER HY. Adverse events related to olanzapine. J Clin Psychiatry 2000; 61 (Suppl 8): 26-9.
13. COULOUVRAT C, DONDEY-NOUVEL L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14 (4): 209-18.
14. DEV VJ, KRUPP P. Adverse event profile and safety of clozapine. Rev Contemp Pharmacother 1995; 6: 197-208.
15. DORTA G, SIEBENMANN R, FRÖHLI P et al. Clozapine-induced cholestatic jaundice. Case report. Z Gastroenterol 1989; 27 (7): 388-90.
16. EGGERT AE, CRISMON ML, DORSON PG et al. Clozapine rechallenge after marked liver enzyme elevation., J Clin Psychopharmacol 1994; 14 (6): 425-6.
17. FULLER MA, SIMON MR, FREEDMAN L. Risperidone-associated hepatotoxicity. J Clin Psychopharmacol 1996; 16 (1): 84-5.
18. GAERTNER I, ALTENDORF K, BATRA A et al. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7 263 treatment courses. J Clin Psychopharmacol 2001 21 (2): 215-22.
19. GELLER WK, ZUIDERWIJK PB. Risperidone-induced hepatotoxicity? J Am Acad Child Adolesc Psychiatry 1998; 37 (3): 246-7.
20. HOVENS JE, VOGTLÄNDER LM, VERHOEVE HA et al. Liver cell necrosis during administration of clozapine. Ned Tijdschr Geneeskd 1994; 138 (7): 363-5.
21. HUMMER M, KURZ M, KURZTHALER I et al. Hepatotoxicity of clopazine. J Clin Psychopharmacol 1997; 17 (4): 314-7.
22. KELLNER M, WIEDEMANN K, KRIEG JC et al. Toxic hepatitis by clozapine treatment. Am J Psychiatry 1993; 150 (6): 985-6.
23. KHAKOO SI, COLES CJ, ARMSTRONG JS et al. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine (« ecstasy ») usage. J Clin Gastroenterol 1995; 20 (3): 244-7.
24. KONIG SA, SCHENK M, SICK C et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia 1999; 40 (7): 1036-40.
25. KREBS S, DORMANN H, MUTH-SELBACH U et al. Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol 2001; 13 (1): 67-9.
26. KUMRA S, HERION D, JACOBSEN LK et al. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997; 36 (5): 701-5.
27. LABORATOIRES JANSSEN USA. Risperidone. Brief summary, 1999.
28. LABORATOIRES LILLY USA. Olanzapine. Brief summary, 2001.
29. LABORATOIRES NOVARTIS USA. Clozapine. PDR, 1999.
30. LANDAU J, MARTIN A. Is liver function monitoring warranted during risperidone treatment ? J Am Acad Child Adolesc Psychiatry 1998; 37 (10): 1007-8.
31. LARSEN JT, CLEMENSEN SV, KLITGAARD NA et al. Clozapine-induced toxic hepatitis. Ugeskr Laeger 2001; 163 (14): 2013-4.
32. LI AP, LU C, BRENT JA et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 1999, 121 (1): 17-35.
33. MACFARLANE B, DAVIES S, MANNAN K et al. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997; 112 (5): 1707-9.
34. MARDER SR, MEIBACH RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-5.
35. MARKOWITZ JS, GRINBERG R, JACKSON C. Marked liver enzyme elevations with clopazine. J Clin Psychopharmacol 1997; 17 (1): 70-1.
36. MAYORAL W, LEWIS JH. Drugs-induced liver disease. Curr Opin Gastroenterol 2000; 16: 231-8.
37. PANAGIOTIS B. Grand mal seizures with liver toxicity in a case of clozapine treatment. J Neuropsychiatry Clin Neurosci 1999; 11 (1): 117-8.
38. PHILLIPS EJ, LIU BA, KNOWLES SR. Rapid onset of risperidone-induced hepatotoxicity. Ann Pharmacother 1998; 32 (7-8): 843.
39. RAZ A, BERGMAN R, EILAM O et al. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001; 321 (2): 156-8.
40. REIN W, COULOUVRAT L, DONDEY-NOUVEL L. Safety profile of amisulpride in short and long-term use. Acta Psychiatr Scand 2000; 101: 23-7.
41. ROQUES V, PERNEY P, BEAUFORT P et al. Acute hepatitis due to ecstasy. Presse Med 1998; 27 (10); 468-70.
42. SCHMIDT G, BÖRSCH G, MOLLER KM et al. Clozapine-induced cholestatic liver lesions. A case study. Dtsch Med Wochenschr 1987; 112 (21): 844-6.
43. SELIM K, KAPLOWITZ N. Hepatotoxicity of psychotropic drugs. Hepatology 1999; 29 (5): 1347-51.
44. SZIGETHY E, WIZNITZER M, BRANICKY LA et al. Risperidone-induced hepatotoxicity in children and adoslescents? A chart review study. J Child Adolesc Psychopharmacol 1999; 9 (2): 93-8.
45. THATCHER GW, CATES M, BAIR B. Clozapine-induced toxic hepatitis. Am J Psychiatry 1995; 152 (2): 296-7.
46. THOMPSON J, CHENGAPPA KN, GOOD CB et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occuring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13 (2): 95-8.
47. TOOLEY PJ, ZUIDERWIJK P. Drug safety. Experience with risperidone. Adv Ther 1997; 14 (5): 262-6.
48. VIDAL, Édition OCP, 2001.
49. WERAPONGSET W, CHAISIRIKUL S, CHRUJIPORN W et al. Efficacy and tolerability of risperidone in chronic schizophrenic thai patients. J Med Ass Thai 1998; 81 (5): 324-8.
50. WHITWORTH AB, LIENSBERGER D, FLEISCHHACKER WW. Transient increase of liver enzymes induced by risperidone: two case reports. J Clin Psychopharmacol 1999; 19 (5): 475-6.
51. WIRSHING WC, AMES D, BISHEFF S et al. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol 1997; 17 (2): 120-1.
52. WORRALL R, WILSON A, CULLEN M. Dystonia and drug-induced hepatitis in a patient treated with clozapine. Am J Psychiatry 1995; 152 (4): 647-8.